Results of different randomized studies comparing chemotherapy to rituximab plus chemotherapy in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
Trial, Median follow-up, Treatment . | Study characteristics . | EFS or FFS, % . | Pvalue . | OS, % . | Pvalue . |
---|---|---|---|---|---|
Abbreviations: CR, complete remission; EFS, event-free survival; FFS, failure-free survival; OS, overall survival; NS, not significant; NA, not available | |||||
*secondary analysis; †both rituximab arms only; ‡for 6×R-CHOP-14 versus 6×CHOP-14 | |||||
GELA10 | DLBCL | EFS | < .0001 | .0004 | |
7 years | 60–80 y | ||||
R-CHOP | All IPI | 42 | 53 | ||
CHOP | Intent-to-treat analysis | 25 | 36 | ||
US Intergroup | |||||
(ECOG/ | DLBCL | ||||
CALGB) study11 | Age >60 y | ||||
3 years | All IPI | FFS | |||
R-CHOP* | Intent-to-treat analysis | 52 | .003 | 67 | .05 |
CHOP | 39 | 58 | |||
2 years* | |||||
R-CHOP | 77 | < .001 | NA | NA | |
R-CHOP + MR | 79 | ||||
CHOP + MR | 74 | ||||
CHOP | 45 | ||||
MinT14 | EFS | ||||
3 years | |||||
DLBCL | |||||
R-chemotherapy | age < 60 y | 79 ± | < .0001 | 93 | .0001 |
chemotherapy | IPI score 0–1 | 59 | 84 | ||
Intent to treat analysis | |||||
RICOVER19 | EFS | ||||
3 years | |||||
6×CHOP-14 | DLBCL | 47 | < .001† | 68 | .003‡ |
8×CHOP-14 | Age 61–80 y | 52 | 66 | ||
6×R-CHOP-14 | All IPI | 66 | 78 | ||
8×R-CHOP-14 | 63 | 72 |
Trial, Median follow-up, Treatment . | Study characteristics . | EFS or FFS, % . | Pvalue . | OS, % . | Pvalue . |
---|---|---|---|---|---|
Abbreviations: CR, complete remission; EFS, event-free survival; FFS, failure-free survival; OS, overall survival; NS, not significant; NA, not available | |||||
*secondary analysis; †both rituximab arms only; ‡for 6×R-CHOP-14 versus 6×CHOP-14 | |||||
GELA10 | DLBCL | EFS | < .0001 | .0004 | |
7 years | 60–80 y | ||||
R-CHOP | All IPI | 42 | 53 | ||
CHOP | Intent-to-treat analysis | 25 | 36 | ||
US Intergroup | |||||
(ECOG/ | DLBCL | ||||
CALGB) study11 | Age >60 y | ||||
3 years | All IPI | FFS | |||
R-CHOP* | Intent-to-treat analysis | 52 | .003 | 67 | .05 |
CHOP | 39 | 58 | |||
2 years* | |||||
R-CHOP | 77 | < .001 | NA | NA | |
R-CHOP + MR | 79 | ||||
CHOP + MR | 74 | ||||
CHOP | 45 | ||||
MinT14 | EFS | ||||
3 years | |||||
DLBCL | |||||
R-chemotherapy | age < 60 y | 79 ± | < .0001 | 93 | .0001 |
chemotherapy | IPI score 0–1 | 59 | 84 | ||
Intent to treat analysis | |||||
RICOVER19 | EFS | ||||
3 years | |||||
6×CHOP-14 | DLBCL | 47 | < .001† | 68 | .003‡ |
8×CHOP-14 | Age 61–80 y | 52 | 66 | ||
6×R-CHOP-14 | All IPI | 66 | 78 | ||
8×R-CHOP-14 | 63 | 72 |